Sartorius
Validation of Covalent Immune Recruiters (CIRs) with Synthetic Tumor Immunotherapeutic Applications
Learning Objectives:
• Discover novel trifunctional CIRs that can selectively label serum antibodies and direct immune responses to specific target proteins
• Use of label-free binding assays to obtain kinetic information to quantify covalent labeling of antibodies and evaluate selectivity
• Monitoring target protein binding and antibody recruitment under relevant equilibrium conditions
• Validation of CIRs specificity and selectively in vivo
Dr. Anthony F. Rullo
Assistant Professor-Chemical Immunology, Department of Pathology and Molecular Medicine, McMaster Immunology Research Center, McMaster University
Register for webinar
Dr. Anthony F. Rullo
Validation of Covalent Immune Recruiters (CIRs) with Synthetic Tumor Immunotherapeutic Applications
Topics
Products on related topics
Manufacturers of similar products
White papers on related topics
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
